in Newswire Published on September 17, 2019

Sanofi, Boehringer Ingelheim Hit with Class Action Over Allegedly Unsafe Levels of Probable Carcinogen NDMA in Zantac [DISMISSED]

by Corrado Rizzi

Last Updated on May 12, 2023

Garza et al. v. Sanofi-Aventis U.S. LLC et al.

Filed: September 13, 2019 § 5:19-cv-05772

Zantac makers Sanofi-Aventis U.S. and Boehringer Ingelheim face a class action over the allegedly high NDMA content in the over-the-counter heartburn and indigestion drug.

May 12, 2023 – Zantac Class Action Voluntarily Dismissed

Case Spotlight

Video Game Addiction Lawsuits

How Do I Join a Class Action Lawsuit?

ClassAction.org Newsletter

Stay Current

Sign Up For
Our Newsletter

New cases and investigations, settlement deadlines, and news straight to your inbox.

Last Updated on May 12, 2023 — 9:48 AM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Senior Managing Editor of ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.